{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T17:01:32Z","timestamp":1777914092390,"version":"3.51.4"},"reference-count":129,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Toxicol Pathol"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:p>Ocular toxicity studies are the bedrock of nonclinical ocular drug and drug\u2013device development, and there has been an evolution in experience, technologies, and challenges to address that ensures safe clinical trials and marketing authorization. The expectations of a well-designed ocular toxicity study and the generation of a coherent, integrative ocular toxicology report and subreports are high, and this article provides a pathology\/toxicology consultant\u2019s perspective on achieving that goal. The first objective is to cover selected aspects of study designs for ocular toxicity studies including considerations for contract research organization selection, minipig species selection, unilateral versus bilateral dosing, and in-life parameters based on fit-for-purpose study objectives. The main objective is a focus on a high-quality ocular pathology report that includes ocular histology procedures to meet regulatory expectations and a report narrative and tables that correlate microscopic findings with key ophthalmic findings and presents a clear interpretation of test article-, vehicle-, and procedure-related ocular and extraocular findings with identification of adversity and a pathology peer review. The last objective covers considerations for a high-quality ophthalmology report, which in concert with a high-quality pathology report, will pave the way for a best quality toxicology report for an ocular toxicity study.<\/jats:p>","DOI":"10.1177\/0192623320946712","type":"journal-article","created":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T06:39:03Z","timestamp":1597905543000},"page":"673-699","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":11,"title":["Selected Aspects of Ocular Toxicity Studies With a Focus on High-Quality Pathology Reports: A Pathology\/Toxicology Consultant\u2019s Perspective"],"prefix":"10.1177","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5616-8422","authenticated-orcid":false,"given":"Brian","family":"Short","sequence":"first","affiliation":[{"name":"Brian Short Consulting, LLC, Laguna Beach, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,8,20]]},"reference":[{"key":"bibr1-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1159\/000377636"},{"key":"bibr2-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1111\/aos.13563"},{"key":"bibr3-0192623320946712","unstructured":"CenterWatch. FDA-approved drugs. Accessed February 19, 2020. https:\/\/www.centerwatch.com\/directories\/1067-fda-approved-drugs\/topic\/104-ophthalmology"},{"key":"bibr4-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-803620-4.00029-3"},{"key":"bibr5-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-019-0745-z"},{"key":"bibr6-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-019-0636-3"},{"key":"bibr7-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2019-314443"},{"key":"bibr8-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1177\/0192623307310955"},{"key":"bibr9-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.13-13707"},{"key":"bibr10-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-47385-7_14"},{"key":"bibr11-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.16-21334"},{"key":"bibr12-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2019.05.032"},{"key":"bibr13-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-017-0128-y"},{"key":"bibr14-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1177\/1091581817741840"},{"key":"bibr15-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-018-2498-y"},{"key":"bibr16-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2020.01.057"},{"key":"bibr17-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2016.0195"},{"key":"bibr18-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2018.0067"},{"key":"bibr19-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-015-0280-7"},{"key":"bibr20-0192623320946712","unstructured":"NDA 208742 DEXTENZA (dexamethasone insert) Pharmacology\/Toxicology NDA Review. Approval November 30, 2018. Accessed February 20, 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/208742Orig1s000PharmR.pdf"},{"key":"bibr21-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2018.0126"},{"key":"bibr22-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2016.10.026"},{"key":"bibr23-0192623320946712","unstructured":"BLA 761125. BEOVU (brolucizumab-dbll intravitreal injection) pharmacology\/toxicology BLA review. Approval October 7, 2019. Accessed April 2, 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/761125Orig1s000PharmR.pdf"},{"key":"bibr24-0192623320946712","doi-asserted-by":"publisher","DOI":"10.4155\/tde-2019-0081"},{"key":"bibr25-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.03.036"},{"key":"bibr26-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1177\/0192623318813533"},{"key":"bibr27-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-62703-164-6"},{"key":"bibr28-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2015.0120"},{"key":"bibr29-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2017.03.013"},{"key":"bibr30-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2010.05.008"},{"key":"bibr31-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2010.05.009"},{"key":"bibr32-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1177\/0192623318770379"},{"key":"bibr33-0192623320946712","unstructured":"NDA 125422 JETREA (ocriplasmin intravitreal injection) Pharmacology\/Toxicology BLA Review. Approval October 17, 2012. Accessed May 24, 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/125422Orig1s000PharmR.pdf"},{"key":"bibr34-0192623320946712","first-page":"1","volume":"00","author":"Bantseev V","year":"2019","journal-title":"Retina"},{"key":"bibr35-0192623320946712","unstructured":"Haag V Legrand JJ, Palae B, Liberge P, Forster R. Tolerance of two saline solutions by intravitreal route in the rabbit and minipig. CiToxLAB France, Evreux. Published 2011. Accessed April 19, 2020. https:\/\/www.citoxlab.com\/wp-content\/uploads\/2014\/03\/17-2011_Eurotox_Tolerance-of-2-saline-solutions-by-intravitreal-route-in-the-rabbit-and-minipig.pdf"},{"key":"bibr36-0192623320946712","first-page":"153","volume":"6","author":"Samuelson D","year":"1996","journal-title":"Vet Comp Ophthalmol"},{"key":"bibr37-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-019-0167-9"},{"key":"bibr38-0192623320946712","first-page":"1","author":"Telinius N","year":"2020","journal-title":"Curr Eye Res"},{"key":"bibr39-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1080\/15569527.2016.1178277"},{"key":"bibr40-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2018.11.026"},{"key":"bibr41-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1111\/vop.12665"},{"key":"bibr42-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1002\/bdr2.1100"},{"key":"bibr43-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1177\/0192623315615553"},{"key":"bibr44-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1177\/1091581819867929"},{"key":"bibr45-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.18-26257"},{"key":"bibr46-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2018.02.015"},{"key":"bibr47-0192623320946712","doi-asserted-by":"publisher","DOI":"10.4155\/bio-2018-0047"},{"issue":"523","key":"bibr48-0192623320946712","first-page":"0","volume":"92","author":"Struble C","year":"2014","journal-title":"Acta Ophthalmol"},{"key":"bibr49-0192623320946712","doi-asserted-by":"crossref","unstructured":"Caruso A, F\u00fcth M, Alvarez-S\u00e1nchez R, et al. Ocular half-life of intravitreal biologics in humans and other species: meta-analysis and model-based prediction. Mol Pharm. 2020;17(2):695-709.","DOI":"10.1021\/acs.molpharmaceut.9b01191"},{"key":"bibr50-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.1993.tb04659.x"},{"key":"bibr51-0192623320946712","doi-asserted-by":"publisher","DOI":"10.2174\/1389200033489488"},{"key":"bibr52-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1080\/10611860600992157"},{"key":"bibr53-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2009.0022"},{"key":"bibr54-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1111\/aos.13889"},{"key":"bibr55-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2017.0063"},{"key":"bibr56-0192623320946712","first-page":"23","volume-title":"Assessing Ocular Toxicology in Laboratory Animals. Springer Science + Business Media","author":"Munger R","year":"2013"},{"key":"bibr57-0192623320946712","first-page":"53","volume-title":"Assessing Ocular Toxicology in Laboratory Animals. Springer Science \u00fe Business Media","author":"Nork TM","year":"2013"},{"key":"bibr58-0192623320946712","first-page":"159","volume-title":"Assessing Ocular Toxicology in Laboratory Animals","author":"Ver Hoeve JN","year":"2013"},{"key":"bibr59-0192623320946712","first-page":"143","volume-title":"Ocular Pharmacology and Toxicology","author":"Wilkie DA","year":"2014"},{"key":"bibr60-0192623320946712","doi-asserted-by":"publisher","DOI":"10.2131\/jts.40.295"},{"key":"bibr61-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2015.0071"},{"key":"bibr62-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2017.0021"},{"key":"bibr63-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2017.0108"},{"key":"bibr64-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-78364-2"},{"key":"bibr65-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-5224.2012.01030.x"},{"key":"bibr66-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1002\/9780470939956.ch24"},{"key":"bibr67-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1159\/000316695"},{"key":"bibr68-0192623320946712","unstructured":"NDA 022288 Bepreve (bepotastine besilate ophthalmic solution) Pharmacology\/Toxicology NDA Review. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/022288s000_PharmR.pdf. Approval September 8, 2009. Accessed April 6, 2020."},{"key":"bibr69-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0222850"},{"key":"bibr70-0192623320946712","doi-asserted-by":"publisher","DOI":"10.30802\/AALAS-CM-19-000088"},{"key":"bibr71-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2014.09.002"},{"key":"bibr72-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2014.09.030"},{"key":"bibr73-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.14-16208"},{"key":"bibr74-0192623320946712","first-page":"E3","volume-title":"Annual Scientific Meeting of the European College of Veterinary Ophthalmologists","author":"Occelli L","year":"2016"},{"key":"bibr75-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2020.106873"},{"key":"bibr76-0192623320946712","unstructured":"FDA Guidance for Industry. Nonclinical Safety Evaluation of Reformulated Drug Products and Products Intended for Administration by an Alternate Route. Published October, 2015. https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm079245.pdf. Accessed February 19, 2020."},{"key":"bibr77-0192623320946712","unstructured":"BLA 761125. LUCENTIS (ranibizumab intravitreal injection) pharmacology\/toxicology BLA review. Approval June 30, 2006. Accessed April 2, 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2006\/125156s0000_Lucentis_PharmR.pdf"},{"key":"bibr78-0192623320946712","unstructured":"BLA 761125. EYLEA (aflibercept ophthalmic solution) pharmacology\/toxicology BLA review. Approval November 18, 2011. Accessed April 2, 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/125387Orig1s000PharmR.pdf"},{"key":"bibr79-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.18-26349"},{"key":"bibr80-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1089\/humc.2015.076"},{"key":"bibr81-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1089\/humc.2015.164"},{"key":"bibr82-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.17-22473"},{"key":"bibr83-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.17-22494"},{"key":"bibr84-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1177\/0192623314522109"},{"key":"bibr85-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1177\/0192623317700519"},{"key":"bibr86-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1177\/0192623312474865"},{"key":"bibr87-0192623320946712","first-page":"159","volume-title":"Assessing Ocular Toxicology in Laboratory Animals","author":"Schafer K","year":"2013"},{"key":"bibr88-0192623320946712","first-page":"1","volume-title":"Assessing Ocular Toxicology in Laboratory Animals","author":"Vezina M","year":"2013"},{"key":"bibr89-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.01-12-01331.1981"},{"key":"bibr90-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0036135"},{"key":"bibr91-0192623320946712","first-page":"2518","volume":"14","author":"Mowat FM","year":"2008","journal-title":"Mol Vis"},{"key":"bibr92-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1292\/jvms.14-0447"},{"issue":"4","key":"bibr93-0192623320946712","first-page":"302","volume":"1","author":"Gerke CG","year":"1995","journal-title":"HKMJ"},{"key":"bibr94-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.13-13724"},{"key":"bibr95-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1006\/exer.2002.1181"},{"key":"bibr96-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1046\/j.1463-5224.1999.00077.x"},{"key":"bibr97-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.6.2.4"},{"key":"bibr98-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1080\/01926230601034624"},{"key":"bibr99-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1177\/0192623310395331"},{"key":"bibr100-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1177\/0192623311419525"},{"key":"bibr101-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1080\/01926230490268756"},{"key":"bibr102-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1080\/01926230252824725"},{"key":"bibr103-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2005.05.004"},{"key":"bibr104-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1177\/0192623315623265"},{"key":"bibr105-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1177\/0192623316642527"},{"key":"bibr106-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1177\/0192623316672352"},{"key":"bibr107-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxlet.2019.07.022"},{"key":"bibr108-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1177\/0192623310383991"},{"key":"bibr109-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1293\/tox.31.97S"},{"key":"bibr110-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1177\/0192623318761348"},{"key":"bibr111-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2011.295"},{"key":"bibr112-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1089\/humc.2018.188"},{"key":"bibr113-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1201\/b13783-24"},{"key":"bibr114-0192623320946712","first-page":"219","volume-title":"Assessing Ocular Toxicology in Laboratory Animals","author":"Schafer K","year":"2013"},{"key":"bibr115-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-415759-0.00053-4"},{"key":"bibr116-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1293\/tox.2015-0037"},{"key":"bibr117-0192623320946712","volume-title":"Illustrative Dictionary of Toxicologic Pathology and Safety Sciences","author":"Schuh J","year":"2019"},{"key":"bibr118-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-018-2450-1"},{"key":"bibr119-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1177\/0192623318803854"},{"key":"bibr120-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1177\/0192623318758619"},{"key":"bibr121-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1177\/0192623319844470"},{"key":"bibr122-0192623320946712","doi-asserted-by":"crossref","unstructured":"Helke KL, Nelson KN, Sargeant AM, et al. Background pathological changes in minipigs: a comparison of the incidence and nature among different breeds and populations of minipigs. Toxicol Pathol. 2016;44(3):325\u2013337. Supplemental table for eye and adnexa. Accessed April 19, 2010. https:\/\/journals.sagepub.com\/doi\/suppl\/10.1177\/0192623315611762.","DOI":"10.1177\/0192623315611762"},{"key":"bibr123-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1177\/0192623316681646"},{"key":"bibr124-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1177\/0192623315596382"},{"key":"bibr125-0192623320946712","unstructured":"FDA Draft Guidance for Industry, Pathology Peer Review in Nonclinical Toxicology Studies: Questions and Answers. Published 2019. Accessed April 5, 2020. https:\/\/www.fda.gov\/media\/129533\/download"},{"key":"bibr126-0192623320946712","unstructured":"Re: Comments on Docket No. FDA-2019-16361, pathology peer review in nonclinical toxicology studies: questions and answers (draft guidance document). Published 2020. Accessed June 13, 2020. https:\/\/toxpath.org\/docs\/Peer-Review-Guidance_STP-Comments_Docket-FDA-2019-16361_16Sept2019-1.pdf"},{"key":"bibr127-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1177\/0192623318805743"},{"key":"bibr128-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1111\/vcp.12772"},{"key":"bibr129-0192623320946712","doi-asserted-by":"publisher","DOI":"10.1177\/0192623316677068"}],"container-title":["Toxicologic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0192623320946712","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0192623320946712","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0192623320946712","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T16:41:11Z","timestamp":1777653671000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0192623320946712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,20]]},"references-count":129,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["10.1177\/0192623320946712"],"URL":"https:\/\/doi.org\/10.1177\/0192623320946712","relation":{},"ISSN":["0192-6233","1533-1601"],"issn-type":[{"value":"0192-6233","type":"print"},{"value":"1533-1601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,20]]}}}